Human immunodeficiency virus type 1 (HIV-1), a member of the retrovirus family, is a causative pathogen of acquired immunodeficiency syndrome (AIDS). HIV-1 requires a protease (PR) enzyme, a homodimer of 99 amino acid peptides belonging to the aspartyl protease class, for replication. Further, HIV-1 PR plays a crucial role in the process of viral maturation and infectivity. Thus, searching for HIV-1 PR inhibitors from natural sources has become a promising approach to develop drugs to treat HIV/AIDS [1] .
Acacia pennata (L.) Willd., a plant belonging to the Mimosaceae family, is a perennial woody climber with bipennate leaves that is distributed in regions of South and Southeast Asia. In Vietnam, A. pennata is distributed widely in the northern mountainous provinces and used as a special nutritious vegetable. A. pennata has traditionally been used as a medicinal plant to treat cough, headaches, rheumatism, and fever in certain regions of Vietnam. In addition, A. pennata has been shown to exhibit anti-nociceptive, anti-inflammatory, antioxidant, anti-parasitic, and anti-transcription activity [2] . A. pennata was also found to have 5 compounds with inhibitory activity for β-amyloid aggregation and could be beneficial for Alzheimer's prevention [3] . As part of an ongoing search screening for anti-HIV-1 PR drugs from Vietnamese medicinal plants, we report in this work the isolation, structural elucidation, and anti-HIV-1 PR activity of a new saponin triterpene (1) , as well as the known saponin pitheduloside G (2), isolated from the stems of A. pennata.
In our search for HIV-1 inhibitory compounds, pepsin (an aspartyl protease similar to HIV-1 PR) was used as a target enzyme. An ethanol extract and ethyl acetate fraction from the stems of A. pennata were found to strongly inhibit the activity of pepsin (data not shown). The ethyl acetate fraction was separated and purified by means of a column chromatography method to obtain the new saponin, 21β-O-[(2E)-6-hydroxyl-2,6-dimethyl-2,7-octadienoyl] pitheduloside G (1), along with the known saponin pitheduloside G (2). The structure of pitheduloside G (2, Figure 1 ) was identified by analyzing the spectroscopic data and comparing them with those reported in the literature [4, 5] . 13 C-nuclear magnetic resonance spectroscopy (NMR) data. The NMR spectra suggested that compound 1 is an acylated triterpenoid oligoglycoside [6, 7] . The 13 C-NMR data for compound 1, including distortionless enhancement by polarization transfer (DEPT) and heteronuclear single quantum coherence (HSQC) spectra, showed 62 carbon resonances, 40 of which were assigned to the aglycone and 22 to the sugar portion. Signals from 10 carbons, in addition to those assigned to the triterpene core (see Experimental Section), were observed for the aglycone portion, together with proton signals at δ H 1.29, 1.84, 5.07, 5.26, 5.93, and 6.77; correlation spectroscopic results suggested the presence of a (2E)-6-hydroxy-2,6-dimethylocta-2,7-dienoic acid moiety attached to the triterpene core [7, 8] . with those of similar triterpenes confirmed the aglycone to be machaerinic acid [9, 10] . The NMR spectra of compound 1 displayed four anomeric proton signals at δ (Figure 2 ). Based on the above results, the structure of compound 1 was determined to be 3-O-{β-
This is the first report of this compound isolated from a natural source. Pitheduloside G (2) was isolated for the first time from Pithecellobium dulce plants [4] . However, this is the first report of the natural occurrence of compound 2 from the Acacia genus.
The isolated compounds (1 and 2) were tested for anti-HIV-1 PR activity. As such, the new saponin, 21β-O-[(2E)-6-hydroxyl-2,6-dimethyl-2,7-octadienoyl] pitheduloside G (1), exhibited potent HIV-1 PR inhibitory activity, with a half-maximum inhibitory concentration (IC 50 ) value of 2.0 ± 0.2 µM. In contrast, pitheduloside G (2) was less active, with an IC 50 value of 18 ± 0.5 µM ( Figure 3) . As a reference, maslinic acid, an oleanane triterpenoid and known potent HIV-1 PR inhibitor [11] , showed inhibitory effects on HIV-1 PR with an IC 50 value of 4.1 ± 0.6 µM under the same experimental conditions ( Figure 3C ). These results clearly show that the inhibitory activity of compound 1 is more potent than that of compound 2, indicating that the moiety at C-21 plays an important role in the activity of compound 1. This is the first report regarding anti-HIV-1 PR activity of the isolated saponins 1 and 2. A new anti-HIV-1 protease saponin from Acacia pennata Natural Product Communications Vol. 13 (4) 2018 413
The cytotoxic activity of compounds 1 and 2 against HEK 293T cells was determined using the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) method. The results shown in Figure 4 indicated that compounds 1 and 2 are nontoxic for HEK 293T cells (IC 50 > 0.8 mM). These data suggest that compound 1 may serve as a candidate agent in the development of HIV/AIDS drugs.
Experimental
General: Optical rotation [α] D values were determined on a Jasco P-1020 polarimeter. Infrared (IR) spectra (KBr) were measured on a Perkin-Elmer FTS Fourier-transform infrared (FT-IR) spectrometer. NMR spectra were recorded on a Bruker AM500 FT-NMR spectrometer. Chemical shifts were recorded in parts per million in methanol-d4 (CD 3 OD) with tetramethylsilane (TMS) as an internal reference. Results from the high-resolution electrospray ionization mass spectrometry (HR-ESI-MS) experiments were obtained on a Thermo Scientific LTQ Orbitrap XL™. For column chromatography, silica gel (63-200 µm particle size, Merck) and a RP-C 18 column (75 µm particle size, Merck) were used. Thin-layer chromatography (TLC) was performed using precoated silica gel 60 F 254 and RP-18 F 254S plates. 
Extraction and isolation:
Stems from A. pennata (7.0 kg) were cut into small pieces and macerated three times with 96% ethanol (20 L × 3 times every day for 4 days) at room temperature. After filtration, ethanol (EtOH) from the combined extracts was removed under vacuum to afford a total crude extract (158 g). This extract was dissolved and suspended in H 2 O (1 L) and partitioned successively with n-hexane (2 L × 3), ethyl acetate (EtOAc, 2 L × 3), and butanol (BuOH, 2 L × 3); after evaporation of the solvents the corresponding n-hexane yielded (14 g), EtOAc yielded (36 g), and BuOH yielded (20 g). The EtOAc extract (36 g) was subjected to a silica gel column and eluted with CH 2 Cl 2 -MeOH to yield fractions I-V. Fraction III was rechromatographed on a silica gel column and eluted with a gradient solvent system of CH 2 Cl 2 /MeOH (15:1, 10:1, and 8:1) to obtain 5 fractions (III.1-III.5). Fraction III.4 was separated via an RP-C 18 column and eluted with MeOH/H 2 O (1:2, 1:1, and 2:1) to give 4 fractions (III.4a-d). Fraction III.4c was repeatedly applied to an RP-C 18 column and eluted with MeOH/H 2 O (3:2) to give compound 2 (22 mg). Fraction III.5 was repeatedly purified using an RP-C 18 column and eluted with MeOH/H 2 O (1:1, 2:1, and 3:1) to give compound 1 (9 mg). 6-hydroxyl-2,6-dimethyl-2,7- Enzyme and chemicals: Recombinant HIV-1 PR, HIV-1 PR substrate (L6525), pepsin, and hemoglobin were purchased from Sigma Aldrich (USA).
21β-O-[(2E)-
Pepsin inhibitory activity assay: During the primary screening, plant extracts and their fractions were collected for purification of anti-HIV-1 PR compounds based on pepsin inhibitory activity using an agar diffusion method, with hemoglobin as a substrate.
Preparation of the hemoglobin-containing agar plate was as follows: 0.2 g agar was added to 7 mL acetate buffer (50 mM, pH 2.35) and then boiled. Hemoglobin (Hb, 3 mL, 1%) in 0.01 N HCl was added to the agar solution after cooling to 50-60C, the mixture was then poured onto petri dishes and maintained at room temperature for agar solidification. Small wells (4 mm in diameter at a distance of 1 cm) were perforated on each agar plate.
The extracts and fractions were dissolved in 100% dimethyl sulfoxide (DMSO) at an appropriate volume to reach a final extract concentration of 100 mg/mL (w/v). Sample (10 L) was added to each well and incubated at 37C for 15 min to allow diffusion into the agar plates; pepsin (10 l/well) was then added and the plates were incubated at 37C for 2 h. After incubation, agar plates were washed with deionized water to remove the precipitate and stained with 0.25% Coomassie brilliant blue (CBB) in 40% (v/v) methanol and 7% (v/v) acetic acid in deionized water (methanol:acetate: water) for 1 h and then distained with methanol:acetate: water until the activity zone was clearly observable. Anti-HIV-1 PR activity was calculated based on the active zone diameter being less than that of the control (without inhibitor).
HIV-1 PR activity and inhibition assay:
HIV-1 PR activity was determined according to the method by Richards et al. [12] using the L6525 substrate (Lys-Ala-Arg-Val-Nle-p-nitro-Phe-Glu-AlaNle amide). The assay mixture (300 μL) contained HIV-1 PR assay buffer (100 mM sodium acetate buffer, pH 4.7, containing 0.9 M NaCl, 4 mM ethylene diamine tetraacetic acid [EDTA], 5 mM  mercaptoethanol, and 1 mM CaCl 2 ), 150 ng HIV-1 PR, and 2 µg L6525 substrate. The assays were performed at 37 o C, and the start of the reaction was recorded as the time at which the substrate was added to the mixture. The absorbance of the reaction mixture was measured at 300 nm using a DU 800 spectrophotometer (Beckman Coulter, USA) for 10 min.
To determine anti-HIV-1 PR activity, the test compound (dissolved in DMSO) was incubated with HIV-1 PR at different concentrations for 10 min prior to the addition of substrate. Based on residual activity (Δ experimental × 100%)/Δ control , where Δ is the change in absorbance at 300 nm per min of HIV-1 PR activity), the inhibitory activity of the compound was calculated as a percentage of the residual activity for the control, in which inhibitor was absent (100%). The data are presented as the mean ± standard deviation of 3 determinations.
MTS assay to determine toxicity in HEK 293T cells: HEK 293T cells were maintained in culture flasks and grown as monolayers in Dulbecco's modified Eagle's medium (DMEM, Corning, USA) supplemented with 10% (v/v) fetal calf serum and buffered with 3.7 g/L NaHCO 3 at 37ºC in a CO 2 incubator (5% CO 2 ). Cells were seeded in flat-bottom clear 96-well microplates (Corning, USA) at a density of 10 4 cells/well in 200 µL culture medium. The cultures were incubated for 24 h. The cells were then treated for 48 h with different concentrations of test compounds; each concentration was tested in triplicate at 37ºC and 5% CO 2 . MTS solution (20 µL, CellTiter 96 aqueous non-radioactive cell proliferation assay, Promega, USA) was then added to each well, and the cells were incubated for an additional 2.5 h at 37ºC and 5% CO 2 . The plates were gently rotated and absorbance was measured at 490 nm using a 414 Natural Product Communications Vol. 13 (4) 2018 Nguyen et al. model 680 microplate reader (Bio-Rad, USA). All drug doses were tested using DMSO as a control, and the data are presented as the mean ± standard deviation of 3 determinations. The IC 50 values were defined as the concentration of the test compounds necessary to inhibit 50% of the control cell growth using the MTS assay.
Supplementary data: Supplementary data are included as Supporting information.
